Articles

Regulatory review processes are not keeping up with rapidly advancing science and are making the environment for developing new treatments and preventions for deadly and debilitating diseases more difficult.

Got questions regarding the submission process? We’ve got the answers! Here are a few of the most frequently asked questions regarding submitting a proposal.

In this global economy, nearly every competitor has access to big breakthroughs in technology and to the equipment and capital to produce standardized products, but those regions that possess the human capital, with its insights, competencies, and experience will have the competitive advantage.

The buzz at BIO India hones in on the lack of clarity and consistency within the clinical trials process

A new paper in Science from BIO concludes that at this early stage of development, synthetic biology does not pose significant novel threats that are fundamentally different from those faced by the biotechnology industry. The regulatory framework that has been shaping recombinant DNA technology for the past 40 years is generally applicable and relevant.

The U.S. Food and Drug Administration (FDA) announced on August 26 that it will convene its Veterinary Medicine Advisory Committee (VMAC) to consider an application by BIO member AquaBounty technologies for its genetically engineered (GE) AquAdvantage Salmon.

During this period of tremendous growth in both the Indian economy and its healthcare sector, it is a critical time to capitalize on the biotech opportunities available within India.

Vigorous government support has played a key role in encouraging China’s development of a bio-based economy, especially in regard to biofuels. 

What event featured CNN’s Fareed Zakaria, Former DNC Chairman Howard Dean, Republic Strategist Karl Rove, Former British Prime Minister Tony Blair, and the heads of the largest pharmaceutical manufacturers in the world?

Award-winning international trade show is seeking an energetic and seasoned sales talent.

Genetic engineering of agricultural animals could be one of the most interesting and promising fields of biotechnology.

The biotech industry has shrunk dramatically in recent years based primarily on the continued tight capital markets and increased aversion to risk on the part of investors.

Welcome to the Internet Sites of the Biotechnology Industry Organization ("BIO"), the trade association representing the U.S. biotechnology industry.  BIO and any affiliated companies (referred to herein as "BIO," "we," "us," or "our") maintain these sites (each a "BIO Site" and collectively "BIO Sites").  

The contents of the member listings on the BIO Web site may not be reproduced or used in any form without prior written permission from BIO. For more information about members, please refer to the organization's Web site. Web site links are provided below.

 

On July 26, Agriculture Secretary Tom Vilsack announced four new project areas for the Biomass Crop Assistance Program.

We hope you will take some time to explore the new site and see all the exciting changes for yourself!

With more than one-fifth of the world’s population, China is an important market for biotech products and is increasingly a key global player in biotech research, development and manufacturing.

The Health Section develops policy positions that promote biomedical innovation and represent the best interests of BIO member companies with a direct interest in human health. Among the priority issues the Health Section focuses on are matters affecting the healthcare-related regulatory and reimbursement climate, pandemic and biodefense preparedness, publicly-funded scientific research, and personalized medicine. The Health Section is managed by a Section governing body and recommends members to sit on BIO's Board of Directors.

The BIO Food and Agriculture Section is responsible for developing and advancing industry policies on all food and agriculture biotechnology issues related to international affairs, government relations, science and regulatory affairs, and media and public affairs. The Section has its own governing body, and fills four seats on the Board and two seats on the Executive Committee. The Governing Body oversees three policy committees: Production Agriculture, Emerging Plant Technology, and Animal Biotechnology.
Staff Contact: Cathleen Enright

The Emerging Companies Section serves the needs of small to medium size BIO member companies most of whom do not yet have major products approved and on the market. This section has its own governing body and fills one-third of the seats on the board of directors. This section operates to bring their opinion to bear on major issues affecting smaller companies, and to construct programs to enhance their development.
Staff Contact: Cartier Esham

The committee consists of the seven Elected Officers of the Organization, the immediate Past Chair of the Organization, the Vice Chairs of each Section's Governing Board, and At-Large Directors selected from the Full Board by the Chair and approved by the Board. The committee is authorized to exercise all powers of the Full Board, except for certain powers reserved for the Full Board under BIO's Bylaws.
Staff Contact: Tom DiLenge